Opium (Opioid) Addiction – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Opium (Opioid) Addiction – Pipeline Review, H1 2017’, provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction

– The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects

– The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alkermes Plc

Aoxing Pharmaceutical Company Inc

Aquilus Pharmaceuticals Inc

BioCorRx Inc

BioDelivery Sciences International Inc

Camurus AB

Foresee Pharmaceuticals LLC

Heron Therapeutics Inc

Indivior Plc

INSYS Therapeutics Inc

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

Orexo AB

Pfizer Inc

Relmada Therapeutics Inc

Savant HWP Inc

Teva Pharmaceutical Industries Ltd

Titan Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Opium (Opioid) Addiction - Overview 6

Opium (Opioid) Addiction - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Opium (Opioid) Addiction - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 23

Alkermes Plc 23

Aoxing Pharmaceutical Company Inc 23

Aquilus Pharmaceuticals Inc 24

BioCorRx Inc 24

BioDelivery Sciences International Inc 25

Camurus AB 25

Foresee Pharmaceuticals LLC 26

Heron Therapeutics Inc 26

Indivior Plc 27

INSYS Therapeutics Inc 28

Omeros Corp 29

Opiant Pharmaceuticals Inc 29

Orexigen Therapeutics Inc 30

Orexo AB 30

Pfizer Inc 31

Relmada Therapeutics Inc 31

Savant HWP Inc 32

Teva Pharmaceutical Industries Ltd 32

Titan Pharmaceuticals Inc 33

Zynerba Pharmaceuticals Inc 33

Opium (Opioid) Addiction - Drug Profiles 34

(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 34

(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 35

(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 36

(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 37

(buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile 38

18-MC - Drug Profile 44

AQU-010 - Drug Profile 46

buprenorphine hydrochloride - Drug Profile 47

buprenorphine hydrochloride - Drug Profile 50

buprenorphine hydrochloride - Drug Profile 51

buprenorphine hydrochloride depot - Drug Profile 56

buprenorphine hydrochloride ER - Drug Profile 57

buprenorphine hydrochloride long acting - Drug Profile 59

buprenorphine hydrochloride SR - Drug Profile 60

cannabidiol - Drug Profile 63

cannabidiol - Drug Profile 64

Canquit-O - Drug Profile 67

FP-004 - Drug Profile 68

naltrexone hydrochloride - Drug Profile 69

naltrexone hydrochloride - Drug Profile 70

naltrexone hydrochloride SR - Drug Profile 71

OMS-405 - Drug Profile 73

OMS-527 - Drug Profile 75

OREX-1019 - Drug Profile 77

ORP-107 - Drug Profile 78

PF-4363467 - Drug Profile 79

PF-5006739 - Drug Profile 80

Small Molecule to Antagonize D3 Receptor for Opioid Addiction - Drug Profile 81

TEV-90109 - Drug Profile 82

Vaccine for Opioid Addiction - Drug Profile 83

Vaccine for Opium Addiction - Drug Profile 84

Opium (Opioid) Addiction - Dormant Projects 85

Opium (Opioid) Addiction - Discontinued Products 86

Opium (Opioid) Addiction - Product Development Milestones 87

Featured News & Press Releases 87

Appendix 100

Methodology 100

Coverage 100

Secondary Research 100

Primary Research 100

Expert Panel Validation 100

Contact Us 100

Disclaimer 101

List of Tables

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Opium (Opioid) Addiction – Pipeline by Alkermes Plc, H1 2017

Opium (Opioid) Addiction – Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by Aquilus Pharmaceuticals Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by BioCorRx Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by BioDelivery Sciences International Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by Camurus AB, H1 2017

Opium (Opioid) Addiction – Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Opium (Opioid) Addiction – Pipeline by Heron Therapeutics Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by Indivior Plc, H1 2017

Opium (Opioid) Addiction – Pipeline by INSYS Therapeutics Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by Omeros Corp, H1 2017

Opium (Opioid) Addiction – Pipeline by Opiant Pharmaceuticals Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by Orexigen Therapeutics Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by Orexo AB, H1 2017

Opium (Opioid) Addiction – Pipeline by Pfizer Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by Relmada Therapeutics Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by Savant HWP Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Opium (Opioid) Addiction – Pipeline by Titan Pharmaceuticals Inc, H1 2017

Opium (Opioid) Addiction – Pipeline by Zynerba Pharmaceuticals Inc, H1 2017

Opium (Opioid) Addiction – Dormant Projects, H1 2017

Opium (Opioid) Addiction – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports